Putting together a summary on the scale has not moved in since I keep seeing the same questions pop up.
I am not a medical professional (just a well-researched patient) so take this with appropriate salt, but I have compiled info from the clinical trials.
Happy to be corrected by the actual clinicians here — that is the whole point of posting it.
JenPlateau said:The scale has not moved in 3 weeks - I am losing my mind
Gonna push back on this one. The scale has not moved in 3 weeks is not that straightforward in my experience. I have been on this for 12 months and the reality is messier than the trials suggest.
Don't get me wrong — the medication works. But cost accessibility is a real barrier. We should be honest about that.
JenPlateau said:The scale has not moved in 3 weeks - I am losing my mind
This is exactly right. JenPlateau articulated what I have been trying to explain to my doctor for months. The The scale has not moved aspect is the most important factor.
Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.
Verify Your PeptidesClinical perspective on The scale has not moved in 3 weeks - I:
I have managed ~150 patients on GLP-1 therapy and this topic comes up frequently. What the data shows — and what I see in practice — is that proper titration prevents most adverse events.
For this specific question, I would recommend: reviewing the relevant clinical guidelines.
LibrarianMeg said:JenPlateau articulated what I have been trying to explain to my doctor for months
I respect LibrarianMeg perspective but I think this oversimplifies things a bit. Re: The scale has not moved in 3 — the effect size varies considerably by population.
I am not saying LibrarianMeg wrong entirely — just that the picture is more nuanced than a blanket statement. The SURMOUNT data specifically shows baseline BMI-dependent responses.